Inotiv, Inc.
DelistedCIK 720154fmd_06J94J0BXX0YETHBFE3HNPPMBAServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Oct 01, 2009 to Mar 31, 2026, 64 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 20 | 24 | 26 | 44 | 60 | 90 | 548 | 572 | 491 | 513 |
| Cost of revenue | 16 | 17 | 18 | 30 | 42 | 59 | – | – | – | – |
| Gross profit | 4 | 8 | 8 | 14 | 18 | 30 | – | – | – | – |
| Research and development | 0 | 0 | 1 | 1 | 1 | 0 | – | – | – | – |
| Total operating expenses | 7 | 6 | 8 | 14 | 21 | 36 | – | – | – | – |
| Operating income | (3) | 1 | 0 | (0) | (3) | (6) | (263) | (81) | (86) | (31) |
| Interest expense | 0 | 0 | 0 | 1 | 1 | 2 | 30 | 43 | 47 | 57 |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 0 | 13 | (59) | 0 | 3 | (0) |
| Income before taxes | (3) | 1 | (0) | (1) | (5) | 6 | (352) | (124) | (131) | (88) |
| Income tax expense | (0) | 0 | (0) | 0 | 0 | (5) | (15) | (19) | (22) | (19) |
| Net income from continuing operations | (3) | 1 | (0) | (1) | (5) | 11 | (337) | (105) | (109) | (69) |
| Net income | (3) | 1 | (0) | (1) | (5) | 11 | (337) | (105) | (108) | (69) |
| Net income to common shareholders | (3) | 1 | (0) | (1) | (5) | 11 | (337) | – | – | – |